Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model

Cancer Gene Therapy

Volumn 4, Issue 2, 1997, Pages 139-144

  Ju, Dian Wen ^a   Cao, Xuetao ^a   Acres, Bruce ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b TRANSGENE S A   (France)

Author keywords

Gene therapy; GM CSF; Macrophage; Melanoma; Recombinant vaccinia virus

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; NITRIC OXIDE; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CELL DEATH; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; MACROPHAGE; MALE; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; PHAGOCYTOSIS; SECRETION; SURVIVAL RATE; VACCINIA;

ANIMALS; CELL DEATH; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; INJECTIONS, INTRALESIONAL; MACROPHAGES; MALE; MELANOMA; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PHAGOCYTOSIS; RECOMBINANT PROTEINS; SURVIVAL RATE; TUMOR CELLS, CULTURED; VACCINIA;

EID: 0031085079     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Foon KA. Biological response modifiers: the new immunotherapy. Cancer Res. 1989;49:1621.
2. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long lasting antitumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
3. Russel SJ. Lymphokine gene therapy for cancer. Immunol Today. 1990;11:196-200.
4. Rosenberg SA. Immunotherapy and gene therapy of cancer. Cancer Res. 1991;51:5074-5079.
5. Rubin JT, Lotze MT. Acute gastric mucosal injury associated with the systemic administration of interleukin 4. Surgery. 1992;111:274-280.
6. Weir JP, Elkins KL. Replication-incompetent herpesvirus vector delivery of an interferon alpha gene inhibits human immunodeficiency virus replication in human monocytes. Proc Natl Acad Sci USA. 1993;90:9140-9144.
7. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expressing vector. Proc Natl Acad Sci USA. 1982;79:7415-7419.
8. Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 1991;252:1662-1667.
9. Mullbacher A, Ramshaw IA, Coupar BEH. Vacciniainterleukin 2 recombinant virus of exogenous interleukin 2 does not alter the magnitude or immune response gene defects of the cytotoxic T-cell response to vaccinia virus in vivo. Scand J Immunol. 1989;29:1-6.
10. Bash JA. Recombinant vaccinia virus interleukin-2-infected tumor cell vaccines in immunotherapy of murine colon adenocarcinoma. J Immunother. 1993;1:269-272.
11. Arroyo PJ, Bash JA, Wallack MK. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferonin α murine hepatic metastasis model. Cancer Immunol Immunother. 1990;31:305-311.
12. Abe J, Wakimoto H, Yoshida Y, et al. Antitumor effect induced by granulocyte-macrophage colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol. 1995;121:587-592.
13. Anderson WF. Gene therapy for cancer. Hum Gene Ther. 1994;5:1-2.
14. Acres B, Dott K, Stefani L, Kieny MP. Directed cytokine expression in tumor cells in vivo using recombinant vaccinia virus. Ther Immunol. 1994;1:17-23.
15. Ju DW, Zheng QY, Wang HB, et al. Inhibitory effects of triazolodiazepine on mouse splenocytes and peritoneal macrophages in vitro. Acta Pharmacol Sin. 1994;15:65-68.
16. van de Loosdrecht AA, Nennie E, Ossenkoppele GJ, et al. Cell mediated cytotoxicity against U937 cells by human monocytes and macrophages in a modified colometric MTT assay. J Immunol Methods. 1991;141:15-22.
17. Ding AH, Nathan CF, Stueher DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediated from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141:2407-2412.
18. Tabata N, Ito M, Shimokata K, et al. Expression of fusion regulatory proteins (FRPs) on human peripheral blood monocytes. J Immunol. 1994;153:3256-3266.
19. Sivanandham M, Scoggin SD, Tanaka N, et al. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol Immunother. 1994;38:259-264.
20. Ramshaw I, Ruby J, Ramsay A, et al. Expression of cytokines by recombinant vaccinia virus: a model for studying cytokines in virus infection in vivo. Immunol Rev. 1992;127:157-182.
21. Elkins KL, Ennist DL, Winegar RT, Weir JP. In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum Gene Ther. 1994;5:809-820.
22. Flexner C, Hugin A, Moss B, et al. Prevention of vaccinia virus infection in immunodeficient mice by vector-derived IL-2 expression. Nature. 1987;330:259-262.
23. Whitamn ED, Tsung K, Paxson J, Norton JA. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery. 1994;116:183-188.
24. Ram Z, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993; 53:83-8.
25. Estin CD, Stevenson US, Plowman GD, et al. Recombinant vaccinia virus vaccine against human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA. 1988;85:1052-1056.
26. Kantor J, Irvine K, Abrams S, et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst. 1992;84:1084-1091.
27. McCabe BJ, Irvine KR, Nishimura MI, et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte response. Cancer Res. 1995;55:1741-1747.